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17. CF-RELATED DIABETES
1. INTRODUCTION
jj CF-related diabetes (CFRD) is one of the most common complications of CF. Its preva-
lence increases with age and is higher in adult female patients. It occurs in approximately
js 30% of CF patients aged 18 years and older
js >50% of CF patients aged 50 years and older (80% of those with CFTR variants asso-
ciated with a severe CF phenotype)
jj CFRD is usually clinically silent making screening essential for timely diagnosis. Oral 
glucose tolerance test (OGTT) is the gold standard for CFRD screening and should be 
performed annually. 
jj Milder abnormalities of glucose regulation such as impaired fasting glucose (IFG) and 
impaired glucose tolerance (IGT) usually precede CFRD. 
jj Fasting asymptomatic hypoglycemia and postprandial reactive hypoglycemia are 
common in CF and are associated with inappropriate insulin secretion control (low BMI, 
delayed responsiveness to hyperglycemia, lack of insulin suppression by hypoglycemia). 
While uncomfortable, it is in general not dangerous.
2. PATHOGENESIS AND RISK FACTORS OF CFRD
jj The etiology of CFRD is complex and the mechanisms leading to its development are 
not fully understood:
js CFRD is distinct from type 1 and type 2 diabetes (Table 1). 
js The main defect is insulin insufficiency as a result of the destruction of β-pancreatic 
cells and decreased β-cell function: abnormal CFTR → reduced HCO3
- secretion from 
the pancreatic duct cells into the lumen → pancreatic enzyme precipitation, mucus ac-
cumulation → reduction of pancreatic enzyme secretion, pancreatic tissue destruction 
(see also Chapter “Pathogenesis of CF ”).
js Insulin resistance associated with infection or inflammation also contributes to CFRD. 
Insulin resistance transiently increases during acute pulmonary infections.
js After transplantation the use of systemic corticosteroids and immunosuppressive agents 
increases the incidence of diabetes through multiple mechanisms (direct toxic effect on 
the β-pancreatic cells, decreased insulin secretion, increased insulin resistance).
js The main risk factors for the development of CFRD are shown in Table 2.
3. CLINICAL MANIFESTATIONS OF CFRD AND LONG-TERM OUTCOMES
jj CFRD is usually asymptomatic, its course is insidious and its diagnosis depends largely on 
the screening of asymptomatic patients.
js Symptoms of hyperglycemia, such as polydipsia and polyuria, are rare.
js Diabetic ketoacidosis is uncommon.
js CFRD may present as a decline of nutritional status or pulmonary function tests: 
in this case a high index of clinical suspicion should prompt active investiga-
tions for CFRD.
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 Table 1: Comparison of type 1, type 2 diabetes and CFRD (adapted from1)
Type 1 diabetes Type 2 diabetes CFRD
Clinical features
 Overweight Uncommon Common Uncommon
 Hypertension Uncommon Common Uncommon (except after transplant)
 Dyslipidemia Uncommon Common Uncommon (except after transplant)
 Ketoacidosis Common Uncommon Uncommon
 Microvascular complications Common Common Common
 Macrovascular complications Uncommon Common Uncommon
Pathophysiology
β-cells and islets Autoimmune destruction of β-cell
Marked atrophy and fibrosis of 
islets
Defective function of β-cells
Focal atrophy and amyloid 
deposition of islets
Islet destruction due to exocrine tissue 
destruction
Defective function of remaining β-cells
Insulin status Insulin deficiency Insulin resistance
Relative insulin deficiency
Insulin deficiency
Variable degrees of insulin resistance 
(notably during exacerbations)
 Glucagon-like peptide 1 Normal Normal or decreased 
secretion
Efficacy normal
Decreased secretion
Improved secretion with pancreatic 
enzyme replacement
 Gastric inhibitory 
polypeptide
Normal Normal or decreased 
secretion
Near normal secretion
Decreased efficacy
 Hyperglucagonemia Absent Present Absent
Oxidative stress Increasing evidence of its role Increasing evidence of its 
role
Increasing evidence of its role
 Genetic predisposition HLA D3 and D4 High. Multiple variants. 
TCF7L2
CFTR genotypes associated with 
pancreatic insufficiency
CFTR genotypes associated with more 
severe CF
Family history of type 2 diabetes, non-
CFTR genotypes (e.g. TCF7L2)
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jj Compared to CF without diabetes, CFRD is associated with lower lung function, worse 
nutrition, more frequent hospitalizations and a higher mortality. 
jj The prevalence of long-term complications depends on the duration of diabetes and the 
level of glycemic control.
js Microvascular complications 
 – Nephropathy: moderately increased albuminuria (or ‘microalbuminuria’) has been
reported in 4-21% of CFRD cases. Kidney failure is rare except after transplant.
Note: Patients with CFRD may be at greatest risk of renal tubular damage when
exposed to nephrotoxic drugs (see also Chapter “Renal disease”).
 – Retinopathy: has been reported in 16-36% of cases with CFRD duration of ≥10
years. Blindness has not been reported.
 – Neuropathy: has been reported in 55% of cases with CFRD duration of ≥10 years.
 – The prevalence of CFRD-induced gastroparesis is difficult to determine because
gastroparesis may be present and is common in CF patients with and without CFRD.
js Macrovascular complications (cardiovascular and cerebrovascular disease) are very 
uncommon in CF. Death from atherosclerotic cardiovascular disease has not been 
reported in CF.
4. DIAGNOSTIC CRITERIA
jj The diagnostic criteria of CFRD are the same as for type 1 and type 2 diabetes. They are 
summarized in Table 3. 
jj For the diagnostic criteria during pregnancy see paragraph 10.
5. DIAGNOSTIC TOOLS
jj Fasting plasma glucose (FPG) alone is not recommended as a screening tool for 
CFRD due to its low sensitivity (it will miss diagnosis in patients with CFRD without fasting 
hyperglycemia).
 Table 2: Factors associated with the development of CFRD2,3
Increasing age
Female gender
Pancreatic insufficiency
Mutations causing severe CFTR dysfunction, class I and II mutations
Decreased pulmonary function 
Liver impairment
Treatment with systemic corticosteroids
Treatment with immunosuppressants
Having a sibling with CFRD
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jj Random glucose measurement may identify CFRD but is not sufficiently accurate as a 
screening method. 
jj Glycosylated hemoglobin (HbA1c): abnormal values are diagnostic of CFRD but nor-
mal values cannot be used to exclude the diagnosis as they are usually spuriously low in 
CF. It is not recommended as a screening tool for CFRD due to its low sensitivity. 
jj Oral glucose tolerance test (OGTT) 
js It is the gold standard for CFRD screening (beginning at least by age of 10), 
because results prospectively correlate with prognosis. It should be done in the 
morning and during clinical stability (≥6 weeks after an exacerbation). 
js Preparation:
 – Fasting during the previous ≥8 hours (water is allowed).
 – The patient should have consumed at least 150 g/day of carbohydrate during the 3
days prior to testing (600kcal): this is usually not a problem in CF patients since they
are on high calorie diets.
js The test consists of an oral liquid glucose load of 1.75 g/kg body weight (maximum 
75g), given within max 5 minutes, to fasting patients. Measurements of baseline glucose 
and 2-hour glucose are performed at a minimum, but 30, 60 and 90 minute glucose 
levels are recommended in order to assess for indeterminate glycemia. During the test 
the patient should not eat, drink or perform any strenuous physical activity (should stay 
seated).
js Interpretation of the results is shown in Table 4. Current diagnostic criteria are based 
on fasting glucose and 2-hour glucose. Results of 1-hour glucose have unclear clinical 
implications (except in the case of pregnancy). An increased 1-hour glucose level is 
associated with markers of clinical deterioration. Prospective studies are needed.
js Hypoglycemia during/after OGTT (called reactive hypoglycemia) has been reported in 
7-29.6% of CF patients, so it is important to feed a light snack at the end.
 Table 3: Diagnostic terminology
CFRD 
–  FPG ≥7.0 mmol/l or 126 mg/dl
–  2-hour OGTT plasma glucose ≥11.1 mmol/l or 200 mg/dl
–  Random glucose level ≥11.1 mmol/l (200 mg/dl) in the presence of diabetic symptoms or
–  HbA1c ≥6.5%*
Impaired fasting glucose
–  IFG =5.6-6.9 mmol/l (normal FPG < 5.6 mmol/l) (110-125 mg/dl)
Impaired glucose tolerance
–  IGT = 2-hour OGTT plasma glucose 7.8-11.0 mmol/l (normal < 7.8 mmol/l) (140-199 mg/dl)
Indeterminate glucose tolerance
–  Normal FPG (<5.6 mmol/l, 110 mg/dl) and 2-hour OGTT plasma glucose (<7.8 mmol/l, 140
mg/dl) but increased mid-OGTT glucose levels (≥11.1 mmol/l, 200 mg/dl)
FPG=fasting plasma glucose, IGT= impaired fasting glucose, OGTT: oral glucose tolerance test
*A normal HbA1c cannot exclude CFRD
7 CF-related diabetes MH.indd   4 30/05/18   8:04 PM
57. CF-RELATED DIABETES
jj Continuous glucose monitoring systems (CGMS) or flash glucose monitoring sys-
tem (FGMS) 
js CGMS/FGMS are not recommended for the diagnosis of CFRD. 
js Essentially all CF patients would have abnormal glucose levels by CGMS/FGMS. In 
patients not fulfilling the diagnostic criteria of CFRD, the clinical relevance of glycemic 
excursions observed during CGMS/FGMS is not known. 
 Table 4: Interpretation of oral glucose tolerance testing (OGTT)
Fasting glucose Mid-OGTT glucose*1 2-hour glucose
Normal <5.6 <11.1 <7.8
Impaired fasting glucose 5.6-6.9
Impaired glucose tolerance <11.1 7.8-11.0
Indeterminate glucose 
tolerance
≥11.1 <7.8
CFRD without fasting 
hyperglycemia
<7.0 - >11.1
CFRD with fasting 
hyperglycemia
≥7.0 - >11.1*2
*1Current diagnostic criteria are based on fasting glucose and 2-hour glucose. The clinical implications of 1-hour glucose 
are not clear, except in the case of pregnancy.
*2The presence of fasting hyperglycemia allows CFRD diagnosis without the need of an OGTT. 
Values expressed in mmol/L. 
6. WHEN AND HOW TO SCREEN FOR CFRD
jj Table 5 summarizes routine screening recommendations for CFRD
 Table 5: Routine screening recommendations (patients not known for CFRD)
When How
Annually during clinical stability OGTT (baseline, 2-hour)
Respiratory exacerbation requiring IV  
 antibiotics and/or systemic corticosteroids
FBG and 2-hour postprandial plasma 
glucose levels for the first 48 hours
During enteral feeding Mid and immediate post-feeding plasma 
glucose levels at enteral feeding initiation 
for 48 hours and monthly thereafter
(continued)
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7. MANAGEMENT
jj All patients with CFRD should be referred to a diabetologist and a dietician with 
experience in CFRD.
jj Insulin is the recommended treatment for CFRD.
js Examples of available types of insulin are shown in Table 6.
js The general principles and usual strategies during insulin treatment for CFRD are shown 
in Table 7. 
js An insulin pump can be used to allow more flexibility and better insulin coverage. This 
can be helpful for CFRD in general and especially for patients who have several snacks, 
difficult glycemic control due to gastroparesis and enteral feeding on and off. Patients’ 
concerns about image body issues (i.e. carrying a visible sign of CFRD) are the main 
limiting factor for their use in CFRD. However, advances in insulin pump technology 
allowing smaller and lighter devices to be developed may improve patient comfort.
jj Oral antidiabetics
js Although they are not recommended by the current guidelines for the treatment of 
CFRD, there is published evidence for their use in CFRD.
js A 2016 Cochrane review concluded that there is
 – “no significant conclusive evidence that long-acting insulins, short-acting insulins or
oral hypoglycemic agents have a distinct advantage over one another in controlling
hyperglycemia or clinical outcomes associated with CFRD”.
 – “no demonstrated advantage yet established for using oral hypoglycemic agents
over insulin”.
js In clinical practice oral antidiabetics such as insulin secretagoges may be considered 
in cases of CFRD without fasting hyperglycemia especially if the patient is reluctant to 
start insulin injections. Repaglinide has been used the most. Sulfunylureas and insulin 
sensitizers are not recommended.
js Table 8 summarizes information on oral antidiabetic agents in CFRD.
Pregnancy
 Before pregnancy: when it is planned and 
if the last available normal OGTT was  
 performed >6 months ago
OGTT (baseline, 2-hour)
 During pregnancy: at 12–16 weeks and 
24–28 weeks of gestation
OGTT (baseline,1-hour, 2-hour)
 After pregnancy: at 6-12 weeks after the  
end of pregnancy in patients with gestational 
CFRD (i.e no pregestational CFRD) 
OGTT (baseline, 2-hour)
 Before lung transplantation if the last available 
normal OGTT was performed >6 months ago
OGTT (baseline, 2-hour)
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jj Additional interventions
js Self management education and hypoglycemia education (for practical informa-
tion concerning patient education see ‘Managing CFRD’ at https://www.cff.org/Search.
aspx?topic=214)
js Dietary recommendations (Table 9)
 – CF patients need a high caloric intake to compensate their energy expenditure as-
sociated to inflammation and work of breathing → restriction of caloric intake in
CFRD is NOT recommended → rather adapt insulin treatment according to
caloric intake (and not the other way round).
js Exercise: regular moderate aerobic exercise is recommended for at least 150min/week.
Note: The blood lowering effect of strenuous exercise may last several hours. Consider 
hypoglycemia prevention strategies such as adjusting insulin dose according to the 
activity level and taking a snack. 
js Management of other risk factors such as hyperlipidemia or hypertension. 
jj Areas of investigation
js CFTR modulators
 – In patients with at least one gating mutation, treatment with ivacaftor can improve
insulin secretion and glycemic control.
 – At the time of writing no data are published on the effect of lumacaftor-ivacaftor on
glycemic control.
js Transplantation of the pancreas 
 – Currently, data are very limited concerning pancreas transplantation in CF: a recent
analysis of the United Network for Organ Sharing (UNOS) database showed that
among the 4600 CF patients transplanted between 1987 and 2014, only 28 received
a pancreas transplant (in most cases combined with liver transplants).
 – The procedure is underused because it is not considered life-saving and in cases of
combined transplantation it increases the complexity of the operation and the proba-
bility of complications.
js Transplantation of pancreatic islets
 – It is a less invasive option than pancreatic transplantation. It consists of the isolation
and culture of donor pancreatic islet cells → transplantation by catheterization of the
portal vein or the transverse colic vein. Elevation of plasma C-peptide is measured as
an indicator of islet allograft recovery.
 – There are no studies on the long-term efficacy and safety of this procedure in CF.
 – Only case reports for simultaneous or sequential lung - pancreatic islet transplanta-
tion in cases of brittle diabetes (poor glycemic control with numerous hypoglycemic
episodes) in an attempt to improve glucose stability, decrease insulin requirements
and eliminate hypoglycemic events.
8. MONITORING OF TREATED CFRD
jj Self-measurement of capillary blood glucose levels ≥3 times/day, keeping a diary of 
glucose levels.
jj HbA1c measurement 4 times/year (general target levels <7%)
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 Table 6: Examples of available insulin forms
Type of insulin Examples Onset Peak Duration Administration Usual starting 
dose
Comment
Rapid acting
 Regular Actrapid ® 30-60 min 2-3 h 4-6 h 15-30 min before
meal
N/A Higher risk of hypoglycemia 
compared to lispro or aspart. 
Prescription on a special order
 Lispro
 Aspart
 Glulisin
Humalog ®
Novorapid ®
Apidra ®
<15 min 1-2 h 3-4 h Less than 15 min 
before meal 
N/A
Intermediate acting
 NPH Insulatard ® 90 min 2-12 h 16-22 h Mix well before 
injection
Before meals
N/A Highly variable absorption 
Higher risk of hypoglycemia 
compared to long acting insulin
Long acting
 Detemir Levemir ® 2 h 6-8 h 12-24 h
depending
on dose
1-2 x/day
If 1x/day with evening
meal or at bedtime
10 UI/day or 
0.1-0.2 UI/kg/
day
 Glargine Lantus ® 2 h Absent in 
low dose
24 h 1-2 x/day 0.2 UI/Kg/day
 Degludec Tresiba ® 2-3 h Absent >24 h 1x/day 10 UI/day Steady state after 3-5 days
Premixed
 Lispro Humalog 
Mix ®
10-15 min 1-2 h 16-22 h Within 15 min of a 
meal
N/A
 Aspart NovoMix ® 10-15 min 1-2 h 16-22 h Within 15 min of a 
meal
N/A
Note: Insulin pumps (continuous subcutaneous insulin infusion – CSII) may be used to administer rapid-acting insulin at a basal rate and, 
when necessary, as a bolus
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 Table 7: General principles and strategies during insulin therapy for CFRD
General principles:
• Adjust insulin to match patient’s high calorie diet
• Adjust insulin using carbohydrate counting
• Consider patient’s lifestyle (eating habits, activities)
• Self-care education has a central role in CFRD management
Usual strategy
• Basal insulin (intermediate or long acting insulins)
Usual starting dose (for CFRD with fasting hyperglycemia): Many patients require a 50:50
basal:rapid acting insulin ratio. Some may require lower amounts of basal insulin (residual
insulin secretion). Usual starting dose: 0.25 units/kg/day
Basal insulin may not be required in CFRD without fasting hyperglycemia. In these cases,
meal coverage insulin may be sufficient.
Adjustment: based on fasting glucose level
• Meal coverage
Usual starting dose: rapid acting insulin 0.5-2.0 units per 10 g of carbohydrate
Adjustment:
– If ≥2 units per 10 g of carbohydrate → consider increasing basal insulin
–  If glucose levels pre and 2h postprandially are almost the same → coverage dose is
considered appropriate
–  If glucose levels 2h postprandially are increased → adjust by increments of 0.2-0.5 units
per 10 g of carbohydrate
• Correction dose: depends on activity (eating, exercise)
Usual starting dose: 1 unit of rapid-acting insulin to lower the glucose level by approximately
2- 3 mmol/l
Adjustment: based on 2-hour post prandial glucose level
Special situations:
• Nighttime gastrostomy/nasogastric tube drip feeding:
–  Regular (or rapid insulin analog) and NPH insulin administered before the feeding.
Glucose levels 3-4h into the feeding are used to adapt regular insulin (or rapid insulin
analog) dose. Glucose levels at the end of feeding are used to adapt NPH insulin dose.
– An insulin pump can also be used.
• Infectious exacerbations: Usually higher insulin requirements during exacerbation retur-
ning to baseline need several weeks after recovery.
• Treatment with systemic corticosteroids: Close monitoring at introduction of systemic
corticosteroids (increase insulin dose at least 30 %), during tapering and at the end of treat-
ment to optimize glycemic control.
• Fasting patient (e.g. for an exam): decrease basal insulin by one third, do not administer
rapid acting insulin, consider correcting after a meal.
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 Table 8: Oral antidiabetics available in Switzerland that have been studied or are used in CFRD (adapted from 4,5)
Drug Dose Positive points Negative points and CF-
related concerns
Insulin secretagoges
   Meglitinides Repaglinide
Novonorm®
Repaglinide®
Starting dose 0.5 mg 3x/day 
taken 10 min prior to a meal
Dose adjusted at 1 week 
intervals until optimized 
Usual dose 1-2mg 3x/day
Max dose 12 mg/day
-Insulin insufficiency is the
main mechanism of CFRD
-Repaglinide is the oral an-
tidiabetic studied the most
in CFRD*
-Weight improvement during
the first 6 months of therapy
Inconsistent efficacy
Laboratory data showed 
weak inhibition of CFTR
Nateglinide
Starlix®
Starting dose 60 mg 3x/day 
taken prior to a meal
Usual dose 120 mg 3x/day 
Maximal dose 120 mg 3x/
day
Insulin insufficiency is the 
main mechanism of CFRD 
No studies in CF
Laboratory data showed 
CFTR inhibition
*Randomized controled trials of repaglinide vs placebo and repaglinide vs insulin
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jj CGMS or FGMS may be used in patients treated with insulin to evaluate variations of 
glucose levels and guide adjustments of therapy (for more information on CGMS/
FGMS see in the Supplement S7). In this context, prescription of a CGMS device to a 
patient requires a prior request of reimbursement. Currently, in Switzerland, FGMS is reim-
bursed when prescribed by a diabetologist for a patient on insulin.
9. MONITORING AND PREVENTION OF MICROVASCULAR COMPLICA-
TIONS AND CARDIOVASCULAR RISK FACTORS
jj For patients for whom the true duration of diabetes is known, monitoring for microvascular 
complications should begin after 5 years of diabetes duration and should be performed 
yearly thereafter.
jj For newly diagnosed patients who were not previously screened for diabetes (i.e. the 
duration of CFRD is unknown) monitoring should be performed at diagnosis and yearly 
thereafter.
jj Annual monitoring should include the following
js Retinal exam done by ophtalmologist
js Unine analysis for albuminuria, proteinuria
js Sensory foot testing 
js Lipid profile 
js Blood pressure measurement
 Table 9: Dietary recommendations for CFRD*1
An optimal nutritional status is of major significance in CF and especially in CFRD
Patients should continue their high calorie diet 
–  no diet restrictions (dietary recommendations for diabetes type 1 or 2 do not apply in CFRD)
–  addition of oral supplements or enteral feeding may be necessary to meet the caloric
requirements
Carbohydrate monitoring is recommended to optimize glycemic control and insulin treatment*2
Avoidance of sugar containing beverages between meals (preferably taken with meals or 
snacks)
Calories 120-150% of normal caloric intake for age and gender
Fat 40% of total energy
Carbohydrates 40-50% of total energy. Individualized consumption with carbohydrate
monitoring
Protein 200% of reference nutrient intake
Salt Unrestricted intake
Fibre Encouraged if it does not compromise energy intake
Vitamins Routine supplementation
*1 See also Chapter “Nutrition”
*2 For carbohydrate monitoring see https://www.cff.org/Search.aspx?topic=214 
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10. PREGNANCY
jj Pregestational CFRD
js Preconception care to optimize glycemic control and assess for complications.
js Close collaboration of the CF specialists, diabetologists and nutritionists.
jj Gestational CFRD
js Untreated gestational diabetes leads to increased maternal and perinatal morbidity. 
js Screening should be routinelly performed with 75 g OGTT
 – before pregnancy: when pregnancy is planned, if the last available normal OGTT was
performed >6 months ago
 – at 12–16 weeks and 24–28 weeks of gestation
 – at 6-12 weeks after the end of pregnancy in patients with gestational CFRD
js The diagnostic criteria during pregnancy are the following (one pathological value is
needed for diagnosis)
 – Fasting glucose ≥5.1 mmol/l or
 – 1-hour glucose ≥10.0 or
 – 2-hour glucose ≥8.5
11. LUNG TRANSPLANTATION
jj At listing patients should be screened with OGTT (if the last available OGTT was performed 
>6 months ago).
jj During the perioperative period and while the patient receives high dose corticosteroids, 
plasma glucose levels should be monitored closely.
jj Currently, there are no CF-specific screening strategies for the diagnosis of new onset 
diabetes after transplantation (NODAT). 
js FBG and 2-hour postprandial plasma glucose levels should be measured routinely 
during the first month after transplantation. 
js FBG should be measured routinely at clinic visits.
js In patients without fasting hyperglycemia, OGTT should be performed at least annually 
as done in CF patients before lung transplantation.
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Continuous gluCose monitoring systems (Cgms) or flash 
gluCose monitoring system (fgms) 
jj Several different systems are available. In general they consist of a disposable subcu-
taneous glucose sensor and a glucose monitor. The glucose sensor is inserted into the 
subcutaneous tissue → the sensor measures the electrical current generated by the oxida-
tion of interstitial fluid glucose by glucose oxidase every few minutes → data are stored in 
the glucose monitor and can be downloaded providing the pattern of glucose levels over 
several days (up to 14 days with FGMS).
jj Capillary blood glucose measurements taken 4 times daily are used to calibrate the sensor 
in case of CGMS (not needed for FGMS, Freestyle libre® system).
jj The patient keeps a diary of his/her activities and eating habits during the measurement 
period.
jj CGMS/FGMS are not recommended for the diagnosis of CFRD. In patients not fulfilling the 
diagnostic criteria of CFRD, the clinical relevance of glycemic excursions observed during 
CGMS/FGMS is not known. 
jj CGMS/FGMS are considered useful in patients diagnosed with CFRD to evaluate varia-
tions of glucose levels and to guide insulin therapy.
jj figure s1 shows an example of a CGMS recording.
s7. Cf-related diabetes
figure s1: example of a Cgms recording a) curves obtained on each day are 
represented by a different color and the mean by the dotted line, b) descriptive 
statistics of daily glucose levels, c) percentage of time during which glucose levels 
are above 7.8 mmol/l, between 3.9 and 7.8 mmol/l and below 3.9 mmol/l.
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